Measuring and Enhancing Creativity and Brain Flexibility in Adolescents With Depression
18 maj 2026 uppdaterad av: University of Minnesota
This research is designed to find out if engaging in creative activities will help adolescents with depression have more flexible thinking, start to see and appreciate their own talents, and develop a more positive view of themselves and their future.
Studieöversikt
Studietyp
Interventionell
Inskrivning (Faktisk)
160
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
Tar emot friska volontärer
Ja
Beskrivning
Inclusion Criteria:
- age 12-17 years
- Phase 1: no clinical diagnosis required.
- Phase 2: presence of at least "mild" depression symptoms as measured by a score of at least 12 on the parent-report Children's Depression Inventory (CDI) (completed in the screening form).
- Phase 2, Summer 2025 East African cohort: The adolescent identifies as East African.
- Phase 2, Summer 2025 Native American cohort: The adolescent identifies as Native American.
Exclusion Criteria:
- any MRI contraindications (e.g., claustrophobia, braces, pregnancy); Note: MRI exclusion is removed for Summer 2023 and 2025 cohorts since the neuroimaging has been removed from the protocol for those cohorts
- neurodevelopmental disorder such as intellectual disability or moderate / severe autism, as indicated by parent report;
- significant medical conditions that would interfere with participating in study activities;
- currently active suicidal ideation, and unable to agree to an appropriate safety plan
- history of significant neurological conditions that might confound MRI analyses (e.g., current and severe epilepsy, brain tumor). Note: this exclusion is removed for Summer 2023 and 2025 cohorts since they will not have MRI.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Creativity Camp
All participants who enrolled in the study were assigned to the Creativity Camp. In Summer 2022, participants were 1:1 randomized to "early" (2 weeks before camp, before camp, after camp) or "late" assessments (before camp, after camp, and 2 weeks after camp). This allowed for an approximation of a waitlist-control design, where we compared the changes during the "waitlist" (the two weeks before camp for the "early" group) to the changes during camp for the "active" group (changes from pre to post intervention for the "late" group) and also allowed us to explore short-term durability of effects in the "late" group. In 2023 and 2025, since MRI was no longer required, clinical data were collected at all 4 time points: 2 weeks before, before camp, after camp, and 2 weeks after camp. This allows for analysis of the data using a "waitlist control" approach while not changing the experience at the level of the participant. |
An 8-day creativity camp that includes a variety of different kinds of creative arts activities.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Child Depression Inventory 2 (CDI-2).
Tidsram: Week 2
|
The CDI (2) is a self-report questionnaire completed by child and parent separately.
The Child CDI 2 is a 28-item measure of depression symptoms for youth ages 7-17.
For each item, participants selected one of three choices that describe the severity of their symptoms over the past 2 weeks.
Responses are: 0 (no symptoms), 1 (mild or probable symptoms), or 2 (definite symptoms).
The 17-item Parent CDI 2, has four choices per item, ranging from 0 (not at all) to 3 (much or most of the time).
For both child and parent reports, higher scores mean more severe depression.
|
Week 2
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The Screen for Child Anxiety Related Disorders (SCARED)
Tidsram: Month 3
|
The SCARED is a 41-item inventory of anxiety symptoms rated on a 3-point Likert-type scale.
Higher scores mean higher severity of anxiety.
|
Month 3
|
|
The Zest for Life Scale (ZLS)
Tidsram: Week 1
|
This 12-item questionnaire assesses engagement, enthusiasm, and positive outlook on life in the last week.
Each of the 12 items is rated on a 9-point Likert scale ranging from 0 (not at all) to 8 (very strongly).
The minimum possible score is 0, and the maximum is 96.
Higher scores on the scale indicate a greater zest for life.
|
Week 1
|
|
The Flourishing Scale
Tidsram: Week 2
|
In this 8-item questionnaire, participants rate on a 1-7 scale their agreement with statements regarding perceptions of their life's meaning and purpose, view of self and how they fit into the world.
Maximum score is 56.
Higher scores mean higher levels of well-being.
|
Week 2
|
|
The Satisfaction with Life Scale
Tidsram: Week 2
|
The Satisfaction with Life Scale assesses overall life satisfaction, with 5 questions on a 1-7 scale.
Maximum score is 35.
Higher scores mean higher life satisfaction.
|
Week 2
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 juni 2022
Primärt slutförande (Faktisk)
31 augusti 2025
Avslutad studie (Faktisk)
31 augusti 2025
Studieregistreringsdatum
Först inskickad
18 maj 2026
Först inskickad som uppfyllde QC-kriterierna
18 maj 2026
Första postat (Faktisk)
26 maj 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
26 maj 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
18 maj 2026
Senast verifierad
1 maj 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PSYCH-2021-30129
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .